NCT05155436View on ClinicalTrials.gov

Occurrence of Dyskalemia With Treatment for Hypertension

PHASE4CompletedINTERVENTIONAL
Enrollment

1,090

Participants

Timeline

Start Date

January 15, 2022

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2023

Conditions
HypertensionPotassium Imbalance
Interventions
DRUG

Fixed Dose Combination pill of Telmisartan 40mg and Amlodipine 5 mg

Participants without prevalent hyperkalemia will receive the fixed-dose combination pill of Telmisartan and Amlodipine, once daily for 3 months.

Trial Locations (1)

1216

National Heart Foundation of Bangladesh, Dhaka

All Listed Sponsors
collaborator

National Heart Foundation Hospital and Research Institute of Bangladesh

UNKNOWN

collaborator

Johns Hopkins University

OTHER

collaborator

Resolve to Save Lives

OTHER

lead

National Heart Foundation of Bangladesh

OTHER